Cipla Targets $19 Billion-a-Year Roche, Amgen Drugs (Update1) - Bloomberg.com
“Avastin, Enbrel, Herceptin -- these are all being marketed today, but the prices are very high,” said Yusuf Hamied, whose father founded the company in 1935, in a telephone interview yesterday. “We will have biosimilars for them.”
No comments:
Post a Comment